These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30427266)

  • 21. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
    Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
    Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
    Flores J; Rito Y; Torres G; Jung H; Treviño-Frenk I; Corona T
    J Neurol Sci; 2015 Jan; 348(1-2):272-3. PubMed ID: 25491264
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.
    Ordoñez-Boschetti L; Rey R; Cruz A; Sinha A; Reynolds T; Frider N; Alvarenga R
    Adv Ther; 2015 Jul; 32(7):626-35. PubMed ID: 26170105
    [TBL] [Abstract][Full Text] [Related]  

    Zięba N; Gębka-Kępińska B; Sowa P
    Wiad Lek; 2022; 75(3):735-741. PubMed ID: 35522887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series.
    Signoriello E; Bonavita S; Sinisi L; Russo CV; Maniscalco GT; Casertano S; Saccà F; Lanzillo R; Morra VB; Lus G
    Mult Scler Relat Disord; 2020 May; 40():101963. PubMed ID: 31986424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
    Christopher KL; Elner VM; Demirci H
    Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fulminant multifocal relapse in a fingolimod-treated multiple sclerosis patient.
    Breville G; Lascano AM; Merkler D; Roth S; Lalive PH
    Mult Scler Relat Disord; 2019 Sep; 34():63-65. PubMed ID: 31229736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod.
    Aramideh Khouy R; Karampoor S; Keyvani H; Bokharaei-Salim F; Monavari SH; Taghinezhad S; Etemadifar M; Esghaei M
    J Neuroimmunol; 2019 Mar; 328():94-97. PubMed ID: 30610966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unusual adverse dermatologic conditions associated with fingolimod and natalizumab in a patient with relapsing remitting multiple sclerosis.
    Mukharesh L; Maloni H; Maiberger M; Chen W; Wallin M
    Clin Neurol Neurosurg; 2020 Aug; 195():105886. PubMed ID: 32470781
    [No Abstract]   [Full Text] [Related]  

  • 30. Hepatitis C during disease modifying therapy with Fingolimod for Relapsing Remitting Multiple Sclerosis: diagnosis and treatment.
    Aslanyan A; Anwar-Hashim Z; Siripurapu R; Mihalova T
    BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ventricular tachycardia after initiation of fingolimod.
    Elounais F; Aburahma A; Alkotob ML; Al Hadidi S
    BMJ Case Rep; 2017 Sep; 2017():. PubMed ID: 28954755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
    Sharim J; Tashjian R; Golzy N; Pouratian N
    J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
    Samaraweera AP; Cohen SN; Akay EM; Evangelou N
    Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
    Walker S; Brew B
    J Clin Neurosci; 2016 Sep; 31():217-8. PubMed ID: 27168454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
    Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
    J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Necrotizing fungal osteomyelitis and fingolimod, 4 years after treatment with fingolimod.
    Harirchian MH; Poursadeghfard M; Sadeghipour A; Kamali H; Sarraf P
    Mult Scler Relat Disord; 2020 Jun; 41():102021. PubMed ID: 32126512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human papillomavirus in the setting of immunodeficiency: Pathogenesis and the emergence of next-generation therapies to reduce the high associated cancer risk.
    Hewavisenti RV; Arena J; Ahlenstiel CL; Sasson SC
    Front Immunol; 2023; 14():1112513. PubMed ID: 36960048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extensive molluscum contagiosum virus infection in a young adult receiving fingolimod.
    Behle V; Wobser M; Goebeler M; Stoevesandt J
    Mult Scler; 2016 Jun; 22(7):969-71. PubMed ID: 26860987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
    Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL
    Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.